ライフサイエンスコーパス: vasopressin receptor

1 lial cells expressing the Galphas-coupled V2 vasopressin receptor.

2 sequestration and desensitization of the V2 vasopressin receptor.

3 en-transmembrane receptor, the Gs-coupled V2 vasopressin receptor.

4 s in the neural distribution of oxytocin and vasopressin receptors.

5 zation of the parathyroid hormone and type 2 vasopressin receptors.

6 properties on the insect and human oxytocin/vasopressin receptors.

7 n receptor is only 30 to 50% homologous with vasopressin receptors.

8 llent selectivity against the human arginine vasopressin receptors.

9 nt series of soluble receptor analogs, named vasopressin receptor 1 elements on a soluble scaffold (V

10 nsitization was investigated by studying two vasopressin receptors 14 and 27 amino acids shorter than

11 Expression of arginine vasopressin receptor 1a (Avpr1a) and oxytocin receptor (

12 ingle 20 mg intravenous dose of the arginine vasopressin receptor 1A (V1a) antagonist, RG7713, on exp

13 ats RS1, RS3 and AVR in the AVPR1A (arginine vasopressin receptor 1a) gene and STin2 in the SLC6A4 (s

14 adrenomedullin, adrenomedullin receptor, and vasopressin receptor 1a.

15 le-nucleotide polymorphism near the arginine vasopressin receptor 1b gene is associated with serious

16 e-nucleotide polymorphism (near the arginine vasopressin receptor 1b gene) was significantly associat

17 n of STAT3 in renal cystic cells depended on vasopressin receptor 2 (V2R) signaling, which increased

18 ncentration mechanism by modulating arginine vasopressin receptor 2 and AQP2 expression in the inner

19 art, to decreased expression of the arginine vasopressin receptor 2 in ptip mutants.

20 mutase 1, lysozyme, serum amyloid A, prions, vasopressin receptor 2, and alpha-1-antitrypsin.

21 First, the vasopressin receptor-2 agonist, dDAVP, was delivered to

22 ture-function relationship studies of the V2 vasopressin receptor, a prototypical G(s)-coupled recept

23 mutations in rhodopsin, cone opsins, the V2 vasopressin receptor, ACTH receptor, and calcium-sensing

24 icate that in cultured cortical neurons, V1a vasopressin receptor activation leads to induction of th

25 ent was activated by phospholipase C-coupled vasopressin receptor activation or by the diacylglycerol

26 from our laboratory has demonstrated that V1 vasopressin receptor agonist (V1 agonist) induces a comp

27 treatment of mpkCCD14 cells with the type 2 vasopressin receptor agonist dDAVP increased mRNA and pr

28 sure of cortical neurons to the selective V1 vasopressin receptor agonist, [Phe2,Orn8]-vasotocin, (V1

29 and-induced endocytosis of two GPCRs: the V2 vasopressin receptor and beta-2 adrenergic receptor, wit

30 from receptor to receptor (400% with type 2 vasopressin receptor and only 30% with M2R), expression

31 ing increased male expression of angiotensin-vasopressin receptor and prolactin receptor, decreased 5

32 ic release of vasopressin and the cloning of vasopressin receptors and of vasopressin-regulated water

33 ectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 (

34 erenol (luteinizing hormone receptor, type 2 vasopressin receptor, and types 1 and 2 beta-adrenergic

35 In patients with advanced heart failure, vasopressin receptor antagonism with conivaptan resulted

36 The first nonpeptide vasopressin receptor antagonist (VRA) is now approved by

37 receptor antagonist), but not by an oxytocin/vasopressin receptor antagonist or a micro-opioid recept

38 Satavaptan (a vasopressin receptor antagonist) was investigated for tr

39 on of [3H]IP1 was blocked by a selective V1a vasopressin receptor antagonist, (Phenylac1, D-Tyr(Me)2,

40 treatment with conivaptan, a dual V(1a)/V(2) vasopressin receptor antagonist, at a single intravenous

41 ct of oral administration of a nonpeptide V2 vasopressin receptor antagonist, OPC 31260, was therefor

42 The effect of V2 vasopressin receptor antagonist, OPC-31260, was then inv

43 Vasopressin receptor antagonists, urea, and loop diureti

44 Vasopressin receptors appear to have a regulatory role i

45 n are identical, but the human V(1)- or V(2)-vasopressin receptors are approximately 80% homologous w

46 Using the GS-coupled V2 vasopressin receptor as a model system, we systematicall

47 Examination of the structure of [Arg(8)]-vasopressin receptors (AVPRs) and oxytocin receptors (OT

48 The human V2 vasopressin receptor belongs to the superfamily of G pro

49 ermitted an alpha s-coupled receptor (the V2 vasopressin receptor but not the beta 2-adrenergic recep

50 Moreover, the m3 muscarinic and the V1a vasopressin receptors but not the GRP receptor also gain

51 alpha q-coupled receptors (bombesin and V1a vasopressin receptors but not the oxytocin receptor) to

52 a fetus is not mediated by stimulation of V1-vasopressin receptors, but is dependent on alpha-adrener

53 t that occupation of a small fraction of V1a vasopressin receptors by AVP results in stimulation of p

54 ion) by vasopressin-induced activation of V2 vasopressin receptors co-expressed at similar levels.

55 ein, the oxytocin receptor, and the arginine vasopressin receptor contain VDREs for activation.

56 The C terminus of the human V2 vasopressin receptor contains multiple phosphorylation s

57 The extracellular portion of the human V2 vasopressin receptor contains one site susceptible to N-

58 e two classes of receptors (beta(2)AR and V2 vasopressin receptors), demonstrate reversal of the patt

59 Among monogamous prairie voles, levels of vasopressin receptor (encoded by the gene avpr1a) in bra

60 The V2 vasopressin receptor expressed transiently was glycosyla

61 d species-specific patterns of oxytocin- and vasopressin-receptor expression in the brain that appear

62 may contribute to the species differences in vasopressin-receptor expression.

63 The vasopressin receptor family is unique among all classes

64 ved for site amino acid replacement rates in vasopressin receptor family proteins (VPRs).

65 The V1a vasopressin receptor, for example, is preferentially lin

66 t changes in the regulation of oxytocin- and vasopressin-receptor gene expression underlie these spec

67 Three Drosophila GPCRs in the vasopressin receptor group respond to crustacean cardioa

68 has a high degree of selectivity toward the vasopressin receptors, >10,000 for hV1a/hV1b and approxi

69 ompulsive disorder, and polymorphisms of V1a vasopressin receptor have been linked to autism.

70 >31000-fold selectivity over all three human vasopressin receptors hV1aR, hV2R, and hV1bR, with no si

71 racellular elements of the human V1-vascular vasopressin receptor (hV1R).

72 The antagonist bound specifically to the V1a vasopressin receptor in crude rat liver membranes with a

73 ansduction mechanism associated with the V1a vasopressin receptor in enriched cultures of cortical ne

74 e value in testing medications targeting the vasopressin receptor in high stress, alcohol-dependent p

75 demonstrate an effector mechanism for the V1 vasopressin receptor in the cerebral cortex and provide

76 s aggression by increasing the number of V1a vasopressin receptors in the AH.

77 s aggression by increasing the number of V1a vasopressin receptors in the anterior hypothalamus (AH).

78 selected for greater potential benefit from vasopressin receptor inhibition, tolvaptan was not assoc

79 phatidylinositol hydrolysis), whereas the V2 vasopressin receptor is selectively coupled to Gs (bioch

80 of this approach, a series of nine mutant V2 vasopressin receptors known to be responsible for X-link

81 93 cells, stimulation of the beta(2)AR or V2 vasopressin receptor leads, respectively, to transient o

82 Vasopressin receptor levels, however, were dramatically

83 s that is initiated by G-protein-coupled V1a vasopressin receptor-mediated cytoplasmic and nuclear Ca

84 n important role for development of oxytocin/vasopressin receptor modulators that would enable clear

85 ace levels of two folding-defective human V2-vasopressin receptor mutants, which were susceptible to

86 hat the naturally occurring loss of function vasopressin receptor mutation R137H, which is associated

87 contractile responses suggests increases in vasopressin receptor number, affinity, and/or efficiency

88 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM,

89 thway for an orphan GPCR referred to here as vasopressin receptor-related receptor 1 (VRR1) by genera

90 has made possible the selective blockade of vasopressin receptor subtypes for therapeutic purposes.

91 luence the HPA axis, such as the vasopressin-vasopressin receptor system.

92 The presence of all known vasopressin receptors that are, together, potentially ca

93 opressin-regulated water channel) and the V2 vasopressin receptor, that are important to regulated wa

94 In contrast to the wild-type vasopressin receptor, the nonsignaling R137H receptor is

95 The V2 vasopressin receptor undergoes ligand-induced sequestrat

96 tide derived from the C terminus of the V(2) vasopressin receptor (V(2)Rpp) or the corresponding unph

97 Reciprocally, Gs enhances IP1 through vasopressin receptor (V1A-R) but not alpha1 adrenergic r

98 ropeptide vasopressin and are prevented by a vasopressin receptor [V1a receptor (V1aR)] antagonist in

99 determine the downstream consequences of V1a vasopressin receptor (V1aR) activation of Ca2+ signaling

100 ure and functional expression of a human V1a vasopressin receptor (V1aR) cDNA isolated from human liv

101 The V1a arginine vasopressin receptor (V1aR) expressed in HEK 293 cells w

102 The V1a vasopressin receptor (V1aR) is a member of a family of r

103 nvestigate whether individual differences in vasopressin receptor (V1aR) or oxytocin receptor (OTR) r

104 recently, we have detected mRNA for the V1a vasopressin receptors (V1aRs) in cultured cortical neuro

105 Palmitoylation of the V2 vasopressin receptor (V2R) and its functional role were

106 nction mutations in the gene encoding the V2 vasopressin receptor (V2R) cause nephrogenic syndrome of

107 tissues through the inhibition of the type-2 vasopressin receptor (V2R) constitutes a validated strat

108 The internalized V2 vasopressin receptor (V2R) expressed in HEK 293 cells is

109 e caused by inactivating mutations in the V2 vasopressin receptor (V2R) gene that result in the loss

110 Stimulation of the V2 vasopressin receptor (V2R) in cultured cells or in vivo

111 Here we demonstrate that a vasopressin receptor (V2R) mutant with truncated third i

112 The V2 vasopressin receptor (V2R) plays a key role in the maint

113 entify molecules that might contribute to V2 vasopressin receptor (V2R) trafficking or signaling, we

114 les in the regulation and function of the V2 vasopressin receptor (V2R), a G protein-coupled receptor

115 hey had gain-of-function mutations in the V2 vasopressin receptor (V2R).

116 y-terminal peptide derived from the human V2 vasopressin receptor (V2Rpp).

117 itineraries of wild type (WT) and mutant V2 vasopressin receptors (V2Rs) in polarized Madin-Darby ca

118 At least four of these five vasopressin receptors were produced by cell lines exempl

119 For class B receptors (e.g. V2 vasopressin receptors), which recycle slowly, beta-arres

120 nant for nephrogenic diabetes insipidus, the vasopressin receptor with a substitution at the DRY moti